Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:1063-1068
Published online before print February 1, 2007, doi: 10.1161/01.STR.0000257981.09329.d2
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/3/1063    most recent
01.STR.0000257981.09329.d2v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Umemura, K.
Right arrow Articles by Hiraga, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Umemura, K.
Right arrow Articles by Hiraga, K.
Related Collections
Right arrow Animal models of human disease
Right arrow Apoptosis
Right arrow Genetically altered mice
Right arrow Acute Cerebral Infarction
Right arrow Brain Circulation and Metabolism
Right arrow Neuroprotectors

(Stroke. 2007;38:1063.)
© 2007 American Heart Association, Inc.


Original Contributions

Neuroprotective Role of Transgenic PAF-Acetylhydrolase II in Mouse Models of Focal Cerebral Ischemia

Kimiko Umemura, MD; Ichiro Kato, MD, PhD; Yutaka Hirashima, MD, PhD; Yoko Ishii, MD, PhD; Takao Inoue, PhD; Junken Aoki, PhD; Nozomu Kono, PhD; Takeshi Oya, MD, PhD; Nakamasa Hayashi, MD, PhD; Hideo Hamada, MD, PhD; Shunro Endo, MD, PhD; Masaya Oda, MD; Hiroyuki Arai, PhD; Hiroyuki Kinouchi, MD, PhD Koichi Hiraga, MD, PhD

From Departments of Neurosurgery (K.U., N.H., H.H., S.E.), Biochemistry (I.K., K.H.), and Pathology (Y.I., T.O), 21st Century COE Program (I.K.), University of Toyama Faculty of Medicine, Toyama, Japan; Department of Physiological Chemistry (Y.H.), Faculty of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan; Graduate School of Pharmaceutical Sciences (T.I., J.A., N.K., H.A.), University of Tokyo, Tokyo, Japan; Department of Neurosurgery (M.O.), Akita University School of Medicine, Akita, Japan; Department of Neurosurgery (H.K.), Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.

Correspondence to Ichiro Kato, Department of Biochemistry and 21st Century COE Program, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Toyama, Japan. E-mail ichikato{at}med.u-toyama.ac.jp

Background and Purpose— Platelet-activating factor (PAF) and oxidized unsaturated free fatty acids have been postulated to aggravate neuronal damage in the postischemic brain. Type II PAF-acetylhydrolase (PAF-AH II) not only terminates signals by PAF by its PAF-hydrolyzing activity but also protects cells against oxidative stress. We examined whether PAF-AH II can rescue cerebral neurons against ischemic insults.

Methods— Transgenic mice overexpressing human PAF-AH II in neurons were generated and enzyme expressions were examined biochemically and histochemically. The mice were subjected to 60 minutes of transient middle cerebral artery occlusion followed by reperfusion for 24 hours. The infarction and apoptosis were estimated by TTC staining and fluorescence TUNEL staining, respectively.

Results— Overexpression of PAF-AH II was found in brains of transgenic mice by Western blot and enzymatic activity analyses. In immunohistochemistry, human PAF-AH II expression was found throughout the central nervous system, especially in neurons of neocortex, hippocampus, and basal ganglia. The neurological deficit scores, cerebral edema index, and relative infarction volume were all significantly (P<0.05) lower in transgenic mice (1.30±0.72, 1.12±0.04, and 14.0±7.7%, respectively) than in wild-type mice (2.56±0.93, 1.23±0.12, and 31.9±9.7%, respectively). Percentages of apoptotic cells were also significantly (P<0.001) lower in transgenic mice (cortex, 5.2±3.3%; hippocampus, 3.4±7.0%) than in wild-type mice (cortex, 41.1±16.9%; hippocampus, 58.9±15.3%).

Conclusions— These results indicate that PAF-AH II exerts strong neuroprotective effects against ischemic injury and suggest a possibility for clinical use of this enzyme in cerebral ischemia.


Key Words: apoptosis • focal ischemia • neuroprotection • PAF-acetylhydrolase • transgenic mice




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. Chen, A. E. Feldstein, and T. M. McIntyre
Suppression of Mitochondrial Function by Oxidatively Truncated Phospholipids Is Reversible, Aided by Bid, and Suppressed by Bcl-XL
J. Biol. Chem., September 25, 2009; 284(39): 26297 - 26308.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Takasawa, I. Kato, K. Takasawa, Y. Ishii, T. Yoshida, M. H. Shehata, H. Kawaguchi, O. M. M. Mohafez, M. Sasahara, and K. Hiraga
Mutation-, Aging-, and Gene Dosage-dependent Accumulation of Neuroserpin (G392E) in Endoplasmic Reticula and Lysosomes of Neurons in Transgenic Mice
J. Biol. Chem., December 19, 2008; 283(51): 35606 - 35613.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Kono, T. Inoue, Y. Yoshida, H. Sato, T. Matsusue, H. Itabe, E. Niki, J. Aoki, and H. Arai
Protection against Oxidative Stress-induced Hepatic Injury by Intracellular Type II Platelet-activating Factor Acetylhydrolase by Metabolism of Oxidized Phospholipids in Vivo
J. Biol. Chem., January 18, 2008; 283(3): 1628 - 1636.
[Abstract] [Full Text] [PDF]